AUS
NZ
UK
CA
USA
IND
Highlights
GSK’s oncology drug Blenrep did not secure backing from a US advisory panel.
The regulatory outcome may affect future revenue projections for the company.
Blenrep had previously been highlighted as a key component within GSK’s pharmaceutical portfolio.
GSK, a major constituent of the UK pharmaceutical industry and listed on the London Stock Exchange under ticker (LON:GSK), is in focus after a development concerning its multiple myeloma therapy, Blenrep. The company's shares are being closely watched during the latest FTSE 100 Live session following feedback from a regulatory meeting in the United States.
Regulatory Decision Puts Blenrep Approval in Question
The Oncologic Drugs Advisory Committee, which works with the US Food and Drug Administration, has voted against the approval of Blenrep. The panel stated that the outcomes associated with the treatment do not outweigh the side effects observed during trials. The FDA often considers such recommendations when deciding on final approvals.
The regulatory authority is expected to deliver its decision within the month. GSK had received a share price boost earlier this week after the FDA published review documents ahead of the meeting, which led to increased attention on the drug's commercial future.
Revenue Stream Expectations Reassessed
Blenrep has been regarded internally as a significant contributor within GSK's late-stage pipeline. Company planning documents had included estimates for strong revenue generation from this therapy, particularly within the US market. The product had been positioned for wide commercial application within the oncology segment.
Recent commentary from the financial sector underscores the shift in sentiment surrounding the asset, noting that peak forecasts for Blenrep have now become less certain. The US market comprises a substantial portion of the product's revenue base, and the advisory committee’s feedback could now alter internal expectations.
Broader Market Context During FTSE 100 Activity
The latest trading day has also seen developments across other UK-listed firms within the FTSE 100 Live feed. Alongside GSK’s headline update, Burberry and Reckitt Benckiser have released business updates, contributing to broader market sentiment. Movements in the British pound and developments in global equity benchmarks have added further context to the day’s trading behavior.
While Blenrep’s FDA pathway remains unresolved, the focus now shifts to the formal outcome of the US agency’s decision later this month. GSK continues to be actively monitored across the UK health care sector and within global pharmaceutical listings on LSE.
